LOGO
Reply to Thread New Thread
Old 11-11-2011, 08:58 PM   #1
FrassyLap

Join Date
Oct 2005
Posts
417
Senior Member
Default US Ok's therapy using human cord blood cells - Say what?
Quote from a knowledgeable industry source concerning this approval:

"The FDA announced yesterday that it had “approved” cord blood transplants for hematologic cancers. This “product approval” comes after the agency told the cord blood industry two years ago that after 20,000+ successful, registry based human transplants over the past 20 years, their medical procedure was really a drug and it needed an IND. Thus an already effective medical procedure has now been “productized”, dramatically increasing its cost without adding any measurably discernable safety."

Look for more of the same from the FDA. This type of regulation is not necessary. After more than 20 years in use and suddenly it needs to be licensed? Insane!




Thu Nov 10, 2011
Nov 10 (Reuters) - U.S. drug regulators have for the first time approved a therapy that uses cells of human blood from the placenta and the umbilical cord to treat people with blood-forming disorders or cancer.

The Food and Drug Administration on Thursday licensed Hemacord, manufactured by the New York Blood Center (NYBC), a therapy that contains self-recreating cells similar to stem cells from human cord blood.

Those blood-forming types of cells, known as progenitor cells, are infused into patients and make their way to bone marrow, where they divide and mature. As they move into the bloodstream, they can help build new blood cells or restore their capacities, including immune function.

Hemacord is approved for use in blood-restoring stem cell transplants, which can use cells from three sources: cords, bone marrow and peripheral blood, the flowing blood that circulates through the body.

"We have been using cord blood for years," said Dr. Machi Scaradavou, medical director of the NYBC's National Cord Blood Program. "Recently, FDA decided that it needs to be licensed and this is the first cord blood product and stem cell product to be licensed."

In 2009, the FDA guided manufacturers of such therapies to submit by Oct. 20 applications either for a license or for an approval as an investigational new drug. National Cord Blood Program is the first to get FDA's nod, Scaradavou said.

"The use of cord blood hematopoietic (blood-forming) progenitor cell therapy offers potentially life-saving treatment options," said Dr. Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement.

Hemacord comes with a boxed warning as it is associated with possibly fatal risks of Graft Versus Host Disease, engraftment syndrome, graft failure and infusion reactions, the FDA said. (Reporting by Alina Selyukh in Washington; Editing by Tim Dobbyn, Bernard Orr)
FrassyLap is offline



Reply to Thread New Thread

« Previous Thread | Next Thread »

Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 

All times are GMT +1. The time now is 09:24 AM.
Copyright ©2000 - 2012, Jelsoft Enterprises Ltd.
Search Engine Optimization by vBSEO 3.6.0 PL2
Design & Developed by Amodity.com
Copyright© Amodity